<DOC>
	<DOCNO>NCT02397382</DOCNO>
	<brief_summary>The purpose study evaluate potential effect single dose 200 milligram ( mg ) guselkumab plasma concentration cocktail representative probe substrates Cytochrome P450 isozymes ( CYP3A4 , CYP2C9 , CYP2C19 , CYP2D6 , CYP1A2 ) participant moderate severe psoriasis .</brief_summary>
	<brief_title>Pharmacokinetic Study Evaluate Effect Single Dose Guselkumab ( CNTO 1959 ) CYP 450 Enzyme Activities After Subcutaneous Administration Participants With Psoriasis</brief_title>
	<detailed_description>This open-label , multi-center study . The total duration study approximately 17 week per participant , include Screening phase ( 4 week prior first probe cocktail administration ) . Participants 4 in-patient period Day 1 , 8 , 15 36 ( 3 period consist 3 day 2 night 1 consist 2 day 1 night ) follow follow period ( Day 92 ) . All Participants receive single 200 mg subcutaneous ( SC ) injection ( 2*100 mg ) guselkumab Day 8 probe cocktail Days 1 , 15 36 . Blood sample collect evaluation pharmacokinetics immunogenicity pre-dose post-dose study treatment . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis without psoriatic arthritis ( PsA ) least 6 month Day 1 Have Psoriasis Area Severity Index ( PASI ) great equal ( &gt; = ) 12 Screening Have Investigator 's Global Assessment ( IGA ) &gt; = 3 Screening Have involve body surface area ( BSA ) &gt; = 10 percent ( % ) Screening Be candidate phototherapy systemic treatment psoriasis Has history current sign symptom severe , progressive , uncontrolled renal , hepatic , cardiac ( include unstable cardiovascular disease , define recent clinical deterioration ( example , unstable angina , rapid atrial fibrillation ) last 3 month cardiac hospitalization within last 3 month ) , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , bleed disorder , rheumatologic , psychiatric , metabolic disturbance Have pulse oximetry value less ( &lt; ) 94 % Screening Genetically determine poor metabolizers CYP2C9 , CYP2C19 , CYP2D6 substrates Is currently undergo previously undergone allergy immunotherapy history anaphylactic reaction Has transplant organ ( exception corneal transplant great ( &gt; ) 3 month Day 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Guselkumab</keyword>
	<keyword>Cytochromes P450</keyword>
</DOC>